Anvita Health updates clinical analytics engine

Clinical analytics service provider Anvita Health has released its Anvita Insight 4.0 clinical analytics engine for care coordination and patient outcomes analysis.

The engine, a middleware tool used to analyze health data, contains the ability to conduct immediate and batch analyses, along with web-based tools for the customization of analyses and reporting, according to the San Diego-based company.

Version 4.0 updates Anvita Insight’s existing capabilities offering a hybrid mode, where data from an EMR or health information exchange (HIE) can be intermixed with medical and pharmaceutical claims data, Anvita stated.

According to the company, the updated system includes two additional tools:
  • Anvita Focus Rules Manager: Allows the end-user to select evidenced-based rules from industry guideline sources, to be used for analysis, assign rule priorities and author their own rules through a web-based user interface.
  • Anvita Insight Viewer: Provides a comprehensive view of the patient or population analyzed. For populations, summary statistics and individual patient lists are displayed for those who have triggered alerts once the analysis is run.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.